Overview and Clinical Importance
Canine Cognitive Dysfunction Syndrome (CDS) is a progressive neurodegenerative disorder affecting senior dogs, analogous to Alzheimer's disease in humans. CDS affects approximately 14-35% of dogs over 8 years of age, with prevalence increasing dramatically with advancing age. Up to 68% of dogs aged 15-16 years may show at least one sign of cognitive impairment. Despite its prevalence, CDS remains significantly underdiagnosed, with studies suggesting only 1.9% of affected dogs receive a formal diagnosis. This condition represents a critical area for the NAVLE due to its clinical significance in geriatric medicine and the growing senior pet population.
| Pathological Change |
Clinical Significance |
| Beta-Amyloid Plaques |
Diffuse extracellular plaques accumulate in cerebral cortex, hippocampus, and frontal lobe. Deposition correlates with severity of cognitive deficits in discrimination learning (r=0.80), reversal learning (r=0.65), and spatial learning (r=0.54) |
| Cerebral Amyloid Angiopathy |
Beta-amyloid deposits in blood vessel walls causing vascular dysfunction and potential microhemorrhages |
| Brain Atrophy |
Progressive cortical atrophy, ventricular enlargement, hippocampal volume reduction, and decreased interthalamic adhesion thickness |
| Neuron Loss |
Selective neuronal loss in hippocampus and cerebral cortex with reduced neurogenesis |
| Oxidative Damage |
Increased toxic free radicals cause oxidative damage to proteins, DNA/RNA, and lipids |
| Glucose Hypometabolism |
Decreased cerebral glucose metabolism leads to reduced brain energy availability and mitochondrial dysfunction |
| Cholinergic Dysfunction |
Impaired cholinergic function contributes to declining cognitive and motor function and disrupted sleep-wake cycles |
Pathophysiology
The pathophysiology of CDS closely parallels human Alzheimer's disease, making dogs a valuable natural model for AD research. The canine amyloid precursor protein (APP) shares approximately 98% amino acid homology with human APP, and dogs develop identical beta-amyloid peptide sequences.
Key Neuropathological Changes
High-YieldUnlike humans with Alzheimer's disease, dogs with CDS do NOT develop neurofibrillary tangles composed of hyperphosphorylated tau protein. This is a key distinguishing feature. All plaques in CDS are of the diffuse subtype and contain intact neurons.
| Category |
Description |
Clinical Examples |
| D - Disorientation |
Spatial awareness deficits and confusion in familiar environments |
Getting lost at home or in familiar places
Getting stuck behind furniture or in corners
Standing on wrong side of door (hinge side)
Staring blankly at walls or into space |
| I - Interactions |
Altered social interactions with people and other animals |
Decreased interest in greeting family members
Failure to recognize familiar people or pets
Increased clinginess or withdrawal
Decreased responsiveness to commands |
| S - Sleep/Wake |
Disrupted sleep-wake cycles |
Nighttime restlessness and pacing
Excessive sleeping during daytime
Nighttime vocalization
Wandering aimlessly at night |
| H - Housesoiling |
Loss of previously learned housetraining |
Urinating or defecating indoors despite prior training
Eliminating shortly after being outside
Forgetting to signal need to go outside |
| A - Activity |
Changes in activity levels |
Decreased interest in play or exploration
Repetitive or purposeless pacing
Increased aimless wandering
Decreased grooming or appetite changes |
| A - Anxiety |
New or worsened anxiety behaviors |
New separation anxiety
Increased fearfulness or phobias
Restlessness and agitation
Vocalization without apparent cause |
Clinical Signs: The DISHAA Acronym
The clinical signs of CDS are characterized by the acronym DISHAA, which organizes behavioral changes into six key domains. A diagnosis of CDS requires impairment in more than one cognitive domain.